广泛期小细胞肺癌一线化疗免疫治疗患者免疫相关不良事件与生存结局的相关性
该多中心回顾性分析纳入2020年1月至2024年9月五个欧洲中心399例接受一线化疗免疫治疗的广泛期小细胞肺癌患者,评估免疫相关不良事件与生存的关系。中位随访15.0个月,30.6%患者发生免疫相关不良事件,发生者中位无进展生存期10.8个月 vs 5.3个月、中位总生存期18.8个月 vs 7.6个月,多因素分析显示免疫相关不良事件与总生存改善相关(HR 0.64)。
要点
- 399例广泛期小细胞肺癌一线化疗免疫治疗患者中,30.6%发生免疫相关不良事件,最常见为皮肤(11.0%)。
- 发生免疫相关不良事件者中位无进展生存期10.8个月 vs 5.3个月(p<0.001),中位总生存期18.8个月 vs 7.6个月(p<0.001)。
- 多因素分析显示免疫相关不良事件与总生存改善相关(HR 0.64;95%CI 0.51-0.80,p<0.001)。
核心结论
- 这项最大规模的回顾性研究显示,在接受一线化疗免疫治疗的广泛期小细胞肺癌患者中,免疫相关不良事件与临床结局改善相关。
研究设计与样本
- 回顾性分析纳入2020年1月至2024年9月五个欧洲中心399例连续接受一线化疗免疫治疗的广泛期小细胞肺癌患者。
- 采用时间依赖Cox回归评估免疫相关不良事件对无进展生存期和总生存期的影响。
主要发现
- 中位随访15.0个月,总体缓解率80.3%,中位无进展生存期6.0个月(95%CI 5.7-6.3),中位总生存期10.4个月(95%CI 9.2-11.6)。
- 30.6%患者发生免疫相关不良事件,最常见为皮肤(11.0%),中位发生时间171天。
- 发生免疫相关不良事件者中位无进展生存期10.8个月 vs 5.3个月(p<0.001),中位总生存期18.8个月 vs 7.6个月(p<0.001)。
- ≥3级免疫相关不良事件患者(n=46)与<3级患者(n=76)之间无显著差异。
- 多因素分析显示免疫相关不良事件与总生存改善相关(HR 0.64;95%CI 0.51-0.80,p<0.001),无进展生存期呈现延长趋势(p=0.028)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Chemo-immunotherapy (CT-IO) has improved median overall survival (mOS) for patients with extensive-stage small cell lung cancer (ES-SCLC), but its association with immune-related adverse events (irAEs) remains unclear. While irAEs are often linked to better outcomes in other cancers, their prognostic value in ES-SCLC is not well understood. METHODS: We conducted a retrospective analysis of 399 consecutive ES-SCLC patients treated with first-line CT-IO between January 2020 and September 2024 across five European centres. Demographic and clinical data were collected. The impact of irAEs on progression-free survival (PFS) and overall survival (OS) was assessed using time-dependent Cox regression. RESULTS: The median follow-up was 15.0 months. The overall response rate was 80.3 %, with a median PFS of 6.0 months (95 % CI 5.7-6.3) and mOS of 10.4 months (95 % CI 9.2-11.6). IrAEs occurred in 30.6 % of patients, most commonly affecting the skin (11.0 %). The median time to onset of irAEs was 171 days. Patients with irAEs had significantly longer mPFS (10.8 vs. 5.3 months, p < 0.001) and mOS (18.8 vs. 7.6 months, p < 0.001) compared to those without. No significant difference was found between patients with grade ≥ 3 (n = 46) and < 3 irAEs (n = 76). Multivariate analysis confirmed that irAEs were associated with improved OS (HR 0.64; 95 % CI 0.51-0.80, p < 0.001) and showed a trend towards longer PFS (p = 0.028). CONCLUSION: This is the largest retrospective study to demonstrate that irAEs are associated with improved clinical outcomes in ES-SCLC pts receiving 1 L CT-IO.
引用
- Monaca F, Gomez-Randulfe I, Parreira AS, et al. Correlation between irAEs and survival outcomes in patients with ES-SCLC treated with first-line chemoimmunotherapy. Eur J Cancer. 2025. PMID: 40250285. doi:10.1016/j.ejca.2025.115435
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。